Patients with a specific type of acute myeloid leukemia have their first treatment option with the FDA’s accelerated approval Tuesday of Idhifa from partners Celgene and Axios.
Blog
More than two years ago, one analyst touted Vertex’s as Gilead’s best option for a buyout that could chip in top-line growth once times got hard in hepatitis C.
Orphan drug sales have nearly doubled since 2008 and sales for the super-pricey drug class will nearly double—again—by 2022 to $209 billion, according to a new industry analysis.
Seattle Genetics has called a halt to all clinical testing of vadastuximab talirine (SGN-CD33A) after seeing a higher rate of patient deaths with the drug in a phase 3 trial.
Amazon said on Friday that it had agreed to buy the upscale supermarket chain Whole Foods for $13.4 billion, in the online retailer’s latest push into the grocery business.
The European Commission made clear this week how it intends to treat API makers from the U.K.
Merck Monday night announced that it was pausing enrollment on a pair of phase 3 multiple myeloma studies of the med to investigate trial deaths.
Sanofi, Gilead said to be eyeing potential $10B deal for prime cancer target Tesaro
Biosim makers scored a big win Monday as the Supreme Court ruled with Sandoz in a much-watched legal dispute with Amgen.
Celgene has landed an option on four natural killer (NK) cell-based blood cancer therapeutics in a deal with Dragonfly Therapeutics.
